Genovis
29.35 SEK +3.89%1,669 investors are following this company
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
31.22
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GENO
Daily low / high price
28.4 / 29.35
SEK
Market cap
1.92B SEK
Turnover
782.59K SEK
Volume
27K
Financial calendar
Interim report
2024-08-20
Interim report
2024-11-08
Annual report
2025-02-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Mikael Lönn | 14.5 % | 14.5 % |
State Street Bank And Trust Co, W9 | 8.4 % | 8.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Genovis AB: Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors
Redeye: GenovisQ1 2024 - Financials in line with expectations, strong outlook
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools